Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roblin

Showing results (671-680 of 756) with videos related to

Pageof 76
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|June 17, 2021
Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseDouglas W Mapel, Melissa H Roberts, Susan Sama, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Frontiers in Immunology|November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's diseaseRémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Pharmaceutics|December 5, 2013
Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan StatisticJeffrey S Brown, Kenneth R Petronis, Andrew Bate, et al.
Addiction (Abingdon, England)|July 11, 2022
The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatmentJason M Glanz, Ingrid A Binswanger, Christina L Clarke, et al.
Science Advances|October 4, 2019
Ruminococcin C, a promising antibiotic produced by a human gut symbiontSteve Chiumento, Clarisse Roblin, Sylvie Kieffer-Jaquinod, et al.
The American Journal of Gastroenterology|August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAIDGilles Boschetti, Maria Nachury, David Laharie, et al.
BMJ Open|December 30, 2017
Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender peopleVirginia P Quinn, Rebecca Nash, Enid Hunkeler, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Pageof 76

Showing results (671-680 of 756) with videos related to

Sort By:
Pageof 76
International Journal of Chronic Obstructive Pulmonary Disease|June 17, 2021
Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseDouglas W Mapel, Melissa H Roberts, Susan Sama, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Frontiers in Immunology|November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's diseaseRémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Pharmaceutics|December 5, 2013
Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan StatisticJeffrey S Brown, Kenneth R Petronis, Andrew Bate, et al.
Addiction (Abingdon, England)|July 11, 2022
The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatmentJason M Glanz, Ingrid A Binswanger, Christina L Clarke, et al.
Science Advances|October 4, 2019
Ruminococcin C, a promising antibiotic produced by a human gut symbiontSteve Chiumento, Clarisse Roblin, Sylvie Kieffer-Jaquinod, et al.
The American Journal of Gastroenterology|August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAIDGilles Boschetti, Maria Nachury, David Laharie, et al.
BMJ Open|December 30, 2017
Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender peopleVirginia P Quinn, Rebecca Nash, Enid Hunkeler, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Pageof 76